Fortrea Holdings (FTRE) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.28
- Estimate
- $0.22
- Surprise
- +28.9%
- Revenue (period 2026-09-30)
- $691.5M
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
Fortrea Holdings (FTRE) beat the $0.22 estimate with adjusted EPS of $0.28 — a large 28.9% upside surprise.
Coverage in the report window
- Citigroup Maintains Buy on Fortrea Holdings, Raises Price Target to $27 — benzinga, 2026-10-30
- Truist Securities Maintains Buy on Fortrea Holdings, Raises Price Target to $29 — benzinga, 2026-10-30
- Barclays Maintains Overweight on Fortrea Holdings, Raises Price Target to $26 — benzinga, 2026-10-30
Where TrendMatrix's rating stands now
TrendMatrix currently rates FTRE Sell at 4.9/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +28.9% surprise compares with a +56.0% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Customer: top ten customers (57.0%)
- Concentration risk — Customer: top 20 customers (69.0%)
- Target reached (1.6% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.23
- Price target
- $20.55
- Stop
- $18.81
- Upside to target
- +1.6%
- Reward-to-risk
- 0.1:1
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
FTRE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.89B
- P/E (fwd)
- 17.6
- 52-week range
- $8.55–$26.16
- Off 52-week high
- 22.7%
- RSI (14)
- 35
- Volume vs avg
- 0.25×
- Score today
- 4.9/10